Mereo Biopharma Group Plc (MPH):企業の財務・戦略的SWOT分析

◆英語タイトル:Mereo Biopharma Group Plc (MPH) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDPH2456548FSA
◆発行会社(調査会社):GlobalData
◆発行日:2021年4月
◆ページ数:25
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イギリス
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD600 ⇒換算¥66,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD900 ⇒換算¥99,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Mereo Biopharma Group Plc (Mereo), formerly Mereo Biopharma Group Ltd is a specialty bio-pharmaceutical company which develops novel medicines for the treatment of rare and specialty diseases. The company’s pipeline products include BPS-804, which is used for the treatment of brittle bone syndrome; and BCT-197, an orally active p38 MAP kinase inhibitor developed for acute exacerbations of chronic obstructive pulmonary disease. Mereo also offers BGS-649, an orally active aromatase inhibitor developed for the treatment of obese men with hypogonadotrophic hypogonadism; and AZD-9668 , an oral neutrophil elastase inhibitor for the treatment of alpha-1 antitrypsin deficiency. The company collaborates with biotechnology and pharmaceutical companies. Mereo is headquartered in London, the UK

Mereo Biopharma Group Plc Key Recent Developments

Mar 31,2021: Mereo BioPharma Reports Full Year 2020 Financial Results and Recent Highlights
Dec 15,2020: Mereo biopharma provides update on AIM delisting and continued listing of its ADSs on Nasdaq, and provides update on agreements with Silicon Valley Bank and Kreos Capital
Nov 23,2020: Mereo BioPharma appoints Suba Krishnan, M.D. as Senior Vice President of Clinical Development
Oct 20,2020: Mereo BioPharma appoints Christine Fox as Chief Financial Officer and Heidi Petersen as Senior Vice President, Regulatory Affairs

This comprehensive SWOT profile of Mereo Biopharma Group Plc provides you an in-depth strategic analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

This company report forms part of GlobalData’s ‘Profile on Demand’ service, covering over 50,000 of the world’s leading companies. Once purchased, GlobalData’s highly qualified team of company analysts will comprehensively research and author a full financial and strategic analysis of Mereo Biopharma Group Plc including a detailed SWOT analysis, and deliver this direct to you in pdf format within two business days. (excluding weekends).

The profile contains critical company information including*,

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note*: Some sections may be missing if data is unavailable for the company.

Key benefits of buying this profile include,

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

【レポートの目次】

Table of Contents

Section 1 – About the Company

Mereo Biopharma Group Plc – Key Information
Mereo Biopharma Group Plc – Overview
Mereo Biopharma Group Plc – Key Employees
Mereo Biopharma Group Plc – Key Employee Biographies
Mereo Biopharma Group Plc – Key Operational Heads
Mereo Biopharma Group Plc – Major Products and Services
Mereo Biopharma Group Plc – History
Mereo Biopharma Group Plc – Company Statement
Mereo Biopharma Group Plc – Locations And Subsidiaries
Mereo Biopharma Group Plc
Head Office
Other Locations & Subsidiaries

Section 2 – Company Analysis

Mereo Biopharma Group Plc – Business Description
Mereo Biopharma Group Plc – Corporate Strategy
Mereo Biopharma Group Plc – SWOT Analysis
SWOT Analysis – Overview
Mereo Biopharma Group Plc – Strengths
Mereo Biopharma Group Plc – Weaknesses
Mereo Biopharma Group Plc – Opportunities
Mereo Biopharma Group Plc – Threats
Mereo Biopharma Group Plc – Key Competitors

Section 3 – Company Financial Performance Charts

Mereo Biopharma Group Plc – Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts

Section 4 – Appendix

Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

Note*: Some sections may be missing if data is unavailable for the company

List of Tables

Mereo Biopharma Group Plc, Key Information
Mereo Biopharma Group Plc, Key Ratios
Mereo Biopharma Group Plc, Share Data
Mereo Biopharma Group Plc, Major Products and Services
Mereo Biopharma Group Plc, History
Mereo Biopharma Group Plc, Key Employees
Mereo Biopharma Group Plc, Key Employee Biographies
Mereo Biopharma Group Plc, Key Operational Heads
Mereo Biopharma Group Plc, Other Locations
Mereo Biopharma Group Plc, Subsidiaries
Mereo Biopharma Group Plc, Key Competitors
Mereo Biopharma Group Plc, SWOT Analysis
Mereo Biopharma Group Plc, Ratios based on current share price
Mereo Biopharma Group Plc, Annual Ratios
Mereo Biopharma Group Plc, Interim Ratios
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

★海外企業調査レポート[Mereo Biopharma Group Plc (MPH):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • City of Hope:企業のM&A・事業提携・投資動向
    City of Hope - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's City of Hope Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, …
  • Yamada Denki Co Ltd:企業の戦略・SWOT・財務分析
    Yamada Denki Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Yamada Denki Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Molkerei Meggle Wasserburg GmbH & Co. KG:企業の戦略・SWOT・財務情報
    Molkerei Meggle Wasserburg GmbH & Co. KG - Strategy, SWOT and Corporate Finance Report Summary Molkerei Meggle Wasserburg GmbH & Co. KG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT …
  • Foraco International SA (FAR):企業の財務・戦略的SWOT分析
    Summary Foraco International SA (Foraco) is a provider of drilling solutions for mining, energy, water and infrastructure projects. The company's drilling solutions include hydrogeological drilling, deep directional drilling, metallurgical sampling and large diameter drilling. It provides geological …
  • Monopar Therapeutics LLC-製薬・医療分野:企業M&A・提携分析
    Summary Monopar Therapeutics LLC (Monopar) is a biopharmaceutical company that develops orphan oncology compounds. The company’s pipeline product include huATN-658, a humanized monoclonal antibody for the potential treatment of various cancers including pancreatic cancer, ovarian cancer, and others. …
  • Hankook Tire & Technology Co Ltd (161390):企業の財務・戦略的SWOT分析
    Hankook Tire & Technology Co Ltd (161390) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strength …
  • IntelGenx Corp:企業のM&A・事業提携・投資動向
    IntelGenx Corp - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's IntelGenx Corp Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestmen …
  • Pt Indofood Sukses Makmur Tbk:企業の戦略・SWOT・財務分析
    Pt Indofood Sukses Makmur Tbk - Strategy, SWOT and Corporate Finance Report Summary Pt Indofood Sukses Makmur Tbk - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Bharat Heavy Electricals Ltd (BHEL):企業の財務・戦略的SWOT分析
    Bharat Heavy Electricals Ltd (BHEL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Teledyne Technologies Incorporated (TDY)-石油・ガス分野:企業M&A・提携分析
    Summary Teledyne Technologies Incorporated (Teledyne) is a provider of instrumentation, digital imaging products and software, aerospace and defense electronics and engineered systems. The company provides electronic subsystems, monitoring instrumentation for marine and environmental applications, h …
  • Oval Medical Technologies Ltd-医療機器分野:企業M&A・提携分析
    Summary Oval Medical Technologies Ltd (Oval Medical), a subsidiary of SMC Ltd is a medical device company that develops revolutionary autoinjectors. The company designs and develops drug delivery devices and drug delivery solutions. Its technologies are used to deliver viscous formulations and sensi …
  • ISMT Limited:企業の戦略・SWOT・財務情報
    ISMT Limited - Strategy, SWOT and Corporate Finance Report Summary ISMT Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Foundation Medicine Inc (FMI):企業の財務・戦略的SWOT分析
    Summary Foundation Medicine Inc (Foundation Medicine), a subsidiary of F. Hoffmann-La Roche Ltd, is a molecular information products provider. The company provides molecular information and cancer research programs. It offers clinical products such as FoundationOne for solid tumors and FoundationOne …
  • Maastricht University:医療機器:M&Aディール及び事業提携情報
    Summary Maastricht University (MU) is an educational service provider that offers academic programs such as bachelor degree, master and doctoral programs. The university offers postgraduate research degrees in various subjects for a range of research needs and interests. It offers programs through i …
  • Astellas Pharma Inc (4503):企業の財務・戦略的SWOT分析
    Astellas Pharma Inc (4503) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Yes Bank Limited:戦略・SWOT・企業財務分析
    Yes Bank Limited - Strategy, SWOT and Corporate Finance Report Summary Yes Bank Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Blueprint Medicines Corp (BPMC):企業の財務・戦略的SWOT分析
    Summary Blueprint Medicines Corp (Blueprint Medicines), formerly Hoyle Pharmaceuticals Inc, discovers and develops precision therapies for the treatment of cancers and rare diseases. The company offers AYVAKIT (avapritinib) medicine to treat gastrointestinal stromal tumor (GIST); and GAVRETO (pralse …
  • Motorola Solutions, Inc.:企業の戦略・SWOT・財務情報
    Motorola Solutions, Inc. - Strategy, SWOT and Corporate Finance Report Summary Motorola Solutions, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Turkiye Petrol Rafinerileri AS (TUPRS):石油・ガス:M&Aディール及び事業提携情報
    Summary Turkiye Petrol Rafinerileri AS (Tupras), a subsidiary of Enerji Yatirimlari AS, is a downstream energy company. It refines crude oil and marketing of petroleum products. The company operates refineries in Izmit, Izmir, Kirikkale and Batman, and is mainly active in Turkey. Tupras’s refineries …
  • Crystal Cruises, LLC:企業の戦略・SWOT・財務情報
    Crystal Cruises, LLC - Strategy, SWOT and Corporate Finance Report Summary Crystal Cruises, LLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆